For five years, insulin manufacturer Novo Nordisk agrees to cap out-of-pocket cost of its insulin treatments at $35 per month, and provide free insulin to the neediest Minnesotans.

Key market drivers of the Insulin Pen and Pump market include the rising prevalence of diabetes, advancements in insulin delivery technologies ...

The Kokomo woman was pre-diabetic when she asked her doctor about Ozempic, the popular anti-diabetic drug. Usually prescribed ...

The Kokomo woman was prediabetic when she asked her doctor about Ozempic, the popular anti-diabetic drug. Usually prescribed ...

The settlement resolves the Attorney General’s 2018 lawsuit alleging that Novo Nordisk deceptively priced its insulin.

Minnesota announced a third and final settlement Monday in its price-fixing lawsuit against the so-called Big Three ...

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

Eli Lilly (NYSE: LLY) has become a beast in healthcare. The excitement surrounding its GLP-1 drugs, Mounjaro and Zepbound, has helped boost its market capitalization to around $650 billion.

The UK injectable drug delivery market is set to grow at 8.80% CAGR through 2034, driven by rising obesity rates and the approval of weight-loss injectable.

Shares of Eli Lilly & Co. were headed for their worst day in nearly four years on Tuesday after the drugmaker provided a fourth-quarter revenue outlook that was below expectations, citing slower ...

Medicare drug plans can now cover Eli Lilly & Co.’s obesity drug Zepbound as a treatment for obstructive sleep apnea, news that’s expected to prove a big boost for the drug company.

Eli Lilly (LLY) Stock Price Prediction in 2025 The current Wall Street consensus 1-year price target of Eli Lilly stock is $1030.00, which is 36.07% higher than today’s price of $756.99.